



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/270,983	03/17/1999	BRUCE A. HAY	06618/284001	3362

7590

06/18/2002

Lisa A. Haile, ph.D  
Gray Cary Ware & Freidenrich LLP  
4365 Executive Drive,  
Suite 1100  
San Diego, CA 92121

PATENT DOCKETING

JUN 21 2002



EXAMINER

HUTSON, RICHARD G

ART UNIT

PAPER NUMBER


1652

DATE MAILED: 06/18/2002

18

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
NOV 25 2002  
TECH CENTER 1600/2900



# Office Action Summary

Application No.

09/270,983

Applicant(s)

HAY ET AL.

Examiner

Richard G Hutson

Art Unit

1652

The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

## A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 02 April 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☒ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

## DETAILED ACTION

### *Continued Prosecution Application*

The request filed on 4/2/2002 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/270,983 is acceptable and a CPA has been established. An action on the CPA follows.

Applicants amendment of claim 1, Paper No. 17, 4/2/2002, is acknowledged.

Claims 1-8 are still at issue and are present for examination.

Applicants' arguments filed on 4/2/2002, paper No. 17, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

### *Drawings*

The drawings are objected to for the reasons listed on the enclosed Form PTO-948.

### *Specification*

The disclosure is objected to because of the following informalities:

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1)

Art Unit: 1652

and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reason(s):

This application does not contain,

- 1) As a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 2) A copy of the "Sequence Listing" in computer readable as required by 37 C.F.R. 1.821(e).
- 3) A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Applicant is referred to Section 2422 of the M.P.E.P., Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications.

The abstract is objected to because it recites "The invention further provides a method of identifying a compound that **activities** a protease." It is believed that this should be recites "The invention further provides a method of identifying a compound that **activates** a protease."

Appropriate correction is required.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1652

Claims 1-8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 (2-8 dependent on) is indefinite in that the recitation "...or active fragment thereof" is unclear in that it is not clear if applicants are referring to the antibody, the transcriptional activator, the enzyme or all three.

Claim 1 (2-8 dependent on) is indefinite in that the recitation "...said repressor polypeptide is operatively linked to the linker polypeptide..." is unclear. Specifically, it is unclear as to what applicants intent is with respect to "operatively". Does this limit the claim or make clear some aspect of the claim?

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4 and 7 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Newly amended claim 1 (2-4 and 7) is rejected because the newly added claim limitation "wherein said reporter is an antibody or active fragment thereof" is not supported by the original disclosure and therefore considered new matter. While it is recognized that the "reporter" may be a polypeptide that contains an epitope that can be

Application/Control Number: 09/270,983

Art Unit: 1652

bound by an antibody, there is no support for the reporter polypeptide being an antibody.

Claims 1, 2, 5, 6 and 8 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1, 2, 5, 6 and 8 are directed to all possible fusion proteins comprising a repressor polypeptide that represses the activity of a reporter polypeptide. The specification, however, only provides the representative species encompassed by these claims, of those fusion proteins comprising a reporter polypeptide which confers a specific localization in the cell such that the attached reporter has reduced activity. There is no disclosure of other types of repressor polypeptides. The specification also fails to describe additional representative species of these repressor polypeptides by any identifying structural characteristics or properties other than the activities recited in claims 1, for which no predictability of structure is apparent. Given this lack of additional representative species as encompassed by the claims, Applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise, and exact terms that a skilled artisan would recognize Applicants were in possession of the claimed invention.

Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at [www.uspto.gov](http://www.uspto.gov).

Claims 1, 2, 5, 6 and 8 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a fusion proteins comprising a repressor polypeptide that confers a specific localization in the cell such that the attached reporter has reduced activity, does not reasonably provide enablement for a fusion protein comprising any repressor polypeptide that represses the activity of a reporter polypeptide. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required, are summarized in *In re Wands* (858 F.2d 731, 8 USPQ 2nd 1400 (Fed. Cir. 1988)) as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claim(s).

Claims 1, 2, 5, 6 and 8 are so broad as to encompass any fusion protein comprising any repressor polypeptide that represses the activity of a reporter polypeptide. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of repressor polypeptides broadly encompassed by the claims, including many of which have not yet been discovered. Reporter/repressor pairs wherein said reporter is an enzyme,

transcriptional activator or antibody are not available in the art nor provided in the specification. What proteins will repress many commonly known reporters such as ~~Δ~~-gal, CAT, GST etc...? Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, in this case the disclosure is limited to those repressor proteins which confer a specific localization in the cell such that the attached reporter has reduced activity.

The specification does not support the broad scope of the claims which encompass fusion proteins comprising any repressor polypeptide because the specification does not establish: (A) regions of the proteins structure which may be modified without effecting reporter/repressor interaction and activity ; (B) the general tolerance of reporter and repressor polypeptides to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying any amino acid residue of reporter/repressor polypeptides with an expectation of obtaining the desired biological function; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful. Because of this lack of guidance, the extended experimentation that would be required to determine which substitutions would be acceptable to retain the reporter/repressor interaction and activity



Application/Control Number: 09/270,983  
Art Unit: 1652

and the fact that the relationship between the sequence of a peptide and its tertiary structure (i.e. its activity) are not well understood and are not predictable (e.g., see Ngo et al. in *The Protein Folding Problem and Tertiary Structure Prediction*, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, Ref: U, Form-892), it would require undue experimentation for one skilled in the art to arrive at the majority of those repressor polypeptides of the claimed genus.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims broadly including a fusion protein comprising any repressor polypeptide. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G Hutson whose telephone number is (703) 308-0066. The examiner can normally be reached on 7:30 am to 4:00 pm, M-F.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (703) 308-3804. The fax phone numbers for the organization where this application or proceeding is assigned

Application/Control Number: 09/270,983

Art Unit: 1652

are (703) 305-3014 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



Richard Hutson, Ph.D.  
Patent Examiner  
Art Unit 1652  
June 17, 2002



REBECCA E. PROUTY  
PRIMARY EXAMINER  
GROUP 1800  
1652